formulation.
"The aryl hydrocarbon receptor represents a truly novel mechanism of action to address the significant unmet needs in inflammatory bowel disease - especially in ulcerative colitis. The ATB team has discovered what we believe to be the best-in-class AhR agonist optimized for safety, gut enrichment, and therapeutic impact. We are delighted to join forces with Dr. Falk Pharma, who has deep expertise in formulation and clinical development. By combining our complementary strengths, we are confident that we will accelerate this program and deliver a much-needed, high-quality therapy to patients faster than ever before," said Yuanhua Ding, CEO of Allianthera.
Kai Pinkernell, M.D., Managing Director, Science & Innovation at Dr. Falk Pharma, added, "We are excited about the addition of ATB102 to our R&D pipeline and to further exploring the potential of this novel molecule in future clinical trials together with Allianthera. The partnership with Allianthera reflects the strength of scientific excellence, mutual trust and a shared vision to better the lives of patients suffering from IBD. This collaboration not only reflects our growing global development and commitment to innovation in areas of high unmet medical need, it will also enhance Dr. Falk Pharma´s portfolio to treat digestive diseases and conditions."
About Ulcerative Colitis Ulcerative colitis is one of the disorders known as inflammatory bowel disease (IBD). Other disorders within this group of conditions include Crohn's disease and two forms of microscopic colitis, called lymphocytic and collagenous colitis.
Ulcerative colitis is confined to the colon and typically begins in the rectum, spreading continuously throughout the rest of the large intestine. The exact cause of ulcerative colitis is still unclear; however immune system dysfunction, genetic factors, gut microbiome imbalance and dysregulation of the intestinal mucosal integrity as well as environmental factors are currently being investigated as potential contributors.
